Gatifloxacin versus ceftriaxone for uncomplicated enteric fever in Nepal: an open-label, two-centre, randomized controlled trial

Gatifloxacin versus ceftriaxone for uncomplicated enteric fever in Nepal: an open-label, two-centre, randomized controlled trial

Background Because treatment with third-generation cephalosporins is associated with slow clinical improvement and high relapse burden for enteric fever, whereas the fluoroquinolone gatifloxacin is associated with rapid fever clearance and low relapse burden, we postulated that gatifloxacin would b...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Arjyal, Amit, Basnyat, Buddha, Nhan, Ho Thi, Koirala, Samir, Giri, Abhishek, Joshi, Niva, Shakya, Mila, Pathak, Kamal Raj, Mahat, Saruna Pathak, Prajapati, Shanti Pradhan, Adhikari, Nabin, Thapa, Rajkumar, Merson, Laura, Gajurel, Damodar, Lamsal, Kamal, Lamsal, Dinesh, Yadav, Bharat Kumar, Shah, Ganesh, Shrestha, Poojan, Dongol, Sabina, Karkey, Abhilasha, Thompson, Corinne N, Thieu, Nga Tran Vu, Thanh, Duy Pham, Baker, Stephen, Thwaites, Guy E, Wolbers, Marcel, Dolecek, Christiane
Natura: Technical Report
Lingua:en_US
Pubblicazione: Lancet Infect Dis 2016 2016
Soggetti:
Gatifloxacin versus
Enteric Fever
Nepal
Accesso online:http://103.69.126.140:8080/handle/123456789/818
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
Descrizione
Riassunto:Background Because treatment with third-generation cephalosporins is associated with slow clinical improvement and high relapse burden for enteric fever, whereas the fluoroquinolone gatifloxacin is associated with rapid fever clearance and low relapse burden, we postulated that gatifloxacin would be superior to the cephalosporin ceftriaxone in treating enteric fever.

Documenti analoghi